Literature DB >> 24366345

Testicular cancer in 2013: towards personalized medicine--are we there yet?

Jan Oldenburg1, Sophie D Fosså1.   

Abstract

The pursuit of reduced-intensity treatments for testicular cancer continued with vigour in 2013. For those with metastatic disease and poor prognoses, an alternative to bleomycin, etoposide and cisplatin chemotherapy emerged. These advances suggest we are making progress by reducing treatment intensity with personalized approaches for this highly curable malignancy.

Entities:  

Mesh：

Year:  2013        PMID： 24366345     DOI： 10.1038/nrurol.2013.298

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  9 in total

1.  Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.

Authors:  Sven-Erik Olofsson; Torgrim Tandstad; Mats Jerkeman; Olav Dahl; Olof Ståhl; Olbjørn Klepp; Roy M Bremnes; Gabriella Cohn-Cedermark; Carl W Langberg; Anna Laurell; Arne Solberg; Ulrika Stierner; Rolf Wahlqvist; Hans Wijkström; Harald Anderson; Eva Cavallin-Ståhl
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

2.  One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group.

Authors:  T Tandstad; O Ståhl; U Håkansson; O Dahl; H S Haugnes; O H Klepp; C W Langberg; A Laurell; J Oldenburg; A Solberg; K Söderström; E Cavallin-Ståhl; U Stierner; R Wahlquist; N Wall; G Cohn-Cedermark
Journal:  Ann Oncol       Date:  2014-08-11       Impact factor: 32.976

3.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

4.  Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J Oldenburg; S D Fosså; J Nuver; A Heidenreich; H-J Schmoll; C Bokemeyer; A Horwich; J Beyer; V Kataja
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

5.  Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.

Authors:  Chunkit Fung; Sophie D Fossa; Michael T Milano; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

Review 6.  Medical treatment of advanced testicular cancer.

Authors:  Darren R Feldman; George J Bosl; Joel Sheinfeld; Robert J Motzer
Journal:  JAMA       Date:  2008-02-13       Impact factor: 56.272

7.  Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma.

Authors:  A Horwich; D P Dearnaley; A Sohaib; K Pennert; R A Huddart
Journal:  Ann Oncol       Date:  2013-04-16       Impact factor: 32.976

8.  Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors.

Authors:  Karim Fizazi; Stéphane Culine; Andrew Kramar; Robert J Amato; Jeannine Bouzy; Isan Chen; Jean-Pierre Droz; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2004-08-09       Impact factor: 44.544

9.  Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.

Authors:  Torgrim Tandstad; Olav Dahl; Gabriella Cohn-Cedermark; Eva Cavallin-Stahl; Ulrika Stierner; Arne Solberg; Carl Langberg; Roy M Bremnes; Anna Laurell; Hans Wijkstrøm; Olbjørn Klepp
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544
  9 in total
  1 in total

Review 1.  The importance of personalized medicine in urological cancers.

Authors:  Fatemeh Khatami; Mandana Hassanzad; Shekoufeh Nikfar; Fateme Guitynavard; Samira Karimaee; Saeyed Saeed Tamehri Zadeh; Keykavos Gholami; AhmadReza Rezaeian; Seyed Ariana Feiz-Abadi; Fatemeh Jahanshahi; Seyed Mohammad Kazem Aghamir
Journal:  J Diabetes Metab Disord       Date:  2021-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.